Positive results from the Phase III APHENITY study have lifted shares in PTC Therapeutics (Nasdaq: PTCT) by around 8%.
The company is testing an oral formulation of synthetic sepiapterin as a treatment for adults and children with phenylketonuria (PKU), a rare and inherited metabolic disease which affects the brain.
PKU is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine (Phe).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze